Study Stopped
No participants were enrolled
Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma
Improved Visualization of Glioblastoma Using Delayed 18F-FDG PET/CT.
3 other identifiers
observational
N/A
1 country
1
Brief Summary
This clinical trial studies how well delayed fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET)/computed tomography (CT) works in improving visualization of brain tumors in patients with glioblastoma. Radiotracers such as 18F-FDG are highly taken up by tumors in the brain and are visualized using PET/CT. Increasing the interval of time between 18F-FDG administration and PET/CT scan may improve the visualization of brain tumors in patients with glioblastoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Jun 2016
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 8, 2016
CompletedFirst Submitted
Initial submission to the registry
August 30, 2016
CompletedFirst Posted
Study publicly available on registry
September 29, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 12, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 12, 2018
CompletedJuly 24, 2020
February 1, 2019
2.5 years
August 30, 2016
July 22, 2020
Conditions
Outcome Measures
Primary Outcomes (2)
Tumor-to-background ratio on delayed scans (240 min after injection)
Ratio between Standardized uptake values (tumor region) and Standardized uptake values (physiological uptake of brain tissue)
Baseline up to 240 minutes after injection
Tumor-to-background ratio on standard scans (60 min after injection)
Ratio between Standardized uptake values (tumor region) and Standardized uptake values (physiological uptake of brain tissue)
Baseline up to 60 minutes after injection
Secondary Outcomes (2)
Standard uptake value comparison
240 minutes post injection
Standard uptake value comparison
60 minutes post injection
Study Arms (1)
Diagnostic (18F-FDG PET/CT)
Patients receive fludeoxyglucose F-18 IV. Patients then undergo a standard of care PET/CT scan at 60 minutes and a second PET/CT scan at 240 minutes after injection.
Interventions
Undergo 18F-FDG PET/CT
Given IV
Undergo 18F-FDG PET/CT
Eligibility Criteria
Patients older than 18 years of age who have been diagnosed with a brain tumor and are undergoing a PET/CT scan..
You may qualify if:
- Patients with histologically proven high grade glioma scheduled for 18F-FDG PET/CT
You may not qualify if:
- Severe psychiatric illness
- Inability to give written consent
- Breast feeding/pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Johannes Czernin
UCLA / Jonsson Comprehensive Cancer Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 30, 2016
First Posted
September 29, 2016
Study Start
June 8, 2016
Primary Completion
December 12, 2018
Study Completion
December 12, 2018
Last Updated
July 24, 2020
Record last verified: 2019-02